Free Cash Flow DeclineA >100% decline in free cash flow is a material structural concern: even with operating cash > net income, negative FCF limits funding for capex, store rollouts or shareholder returns. Without recovery in cash conversion or working capital fixes, growth initiatives may require external financing.
Weak EPS ConversionEPS growth (~2.8%) lags top-line expansion, indicating revenue is not fully translating to per-share earnings. Over the medium term this suggests margin pressure, higher operating or financing costs, or dilution risks, all of which can constrain returns to shareholders and limit redeployment of capital.
Low Net Margin CushionA modest net margin (~3.6%) leaves limited room to absorb cost inflation, wage rises, or competitive pricing. In the retail pharmacy segment small adverse cost or revenue shocks can materially reduce net income and free cash flow, constraining the company’s ability to reinvest or smooth returns.